Avastin market (Microvascular Complications of Diabetes) development and Industry growth by 2022

The entire market for microvascular complications of diabetes (MCD) diabetic nephropathy, retinopathy, and neuropathy is facing an extremely high level of unmet need across the 7MM (US, 5EU and Japan). Despite its enormous potential, the MCD market is facing the major global barrier in the sparsely populated pipeline. The diabetic retinopathy segment of the market has recently seen rapid uptake of novel anti-VEGF therapies and is experiencing a strong growth. On the other hand, the diabetic neuropathy and nephropathy segments face the barrier in and increasing number of generic competitors.

Avastin (bevacizumab) is a recombinant humanized IgG1 mAb that specifically binds to VEGF-A, thereby preventing the interaction of VEGF-A with its receptors on the surface of endothelial cells. Through VEGF-A inhibition, Avastin inhibits angiogenesis, and is indicated for the adjunctive treatment of metastatic colorectal cancer as well as for other types of cancer.

Full report giving a detailed analysis and forecast spread over 58 pages is available at http://www.rnrmarketresearch.com/avastin-microvascular-complications-of-diabetes-forecast-and-market-analysis-to-2022-market-report.html .

Scope

• Overview of MCD, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
• Detailed information on Avastin including product description, safety and efficacy profiles as well as a SWOT analysis.
• Sales forecast for Avastin for the top seven countries from 2012 to 2022.
• Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan.

Reasons to buy

• Understand and capitalize by identifying products that are most likely to ensure a robust return
• Stay ahead of the competition by understanding the changing competitive landscape for MCD
• Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
• Make more informed business decisions from insightful and in-depth analysis of Avastin performance
• Obtain sales forecast for Avastin from 2012-2022 in top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan)

Table of Contents

1 Table of Contents
1 Table of Contents 6
1.1 List of Tables 8
1.2 List of Figures 8

2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 10

3 Disease Overview 12
3.1 Etiology and Pathophysiology 14
3.1.1 Diabetic Nephropathy 14
3.1.2 Diabetic Retinopathy 16
3.1.3 Diabetic Neuropathy 17
3.2 Prognosis 18
3.3 Quality of Life 19
3.4 Symptoms 20

4 Disease Management 21
4.1 Treatment Overview 21
4.1.1 Diagnosis and Referrals 21
4.1.2 Screening 23
4.1.3 Treatment Guidelines 24

5 Competitive Assessment 32
5.1 Overview 32
5.2 Strategic Competitor Assessment 33

Get a Sample of the Report for review and learning at http://www.rnrmarketresearch.com/contacts/request-sample?rname=147160 .

6 Avastin (bevacizumab) 37
6.1 Overview 37
6.2 Efficacy 38
6.3 Safety 39
6.4 SWOT Analysis 40
6.5 Forecast 41

7 Appendix 42
7.1 Bibliography 42
7.2 Abbreviations 47
7.3 Methodology 50
7.4 Forecasting Methodology 50
7.4.1 Diagnosed Patients 50
7.4.2 Percent Drug-Treated Patients 51
7.4.3 General Pricing Assumptions 51
7.4.4 Individual Drug Assumptions 52
7.4.5 Generic Erosion 52
7.5 Physicians and Specialists Included in this Study 53
7.6 About the Authors 55
7.6.1 Analyst II - CVMD 55
7.6.2 Therapy Director - CVMD and Infectious Disease 55
7.6.3 Global Head of Healthcare 56
7.7 About researcher 57
7.8 Disclaimer 57

List of Tables

Table 1: Risk Factors for MCD 14
Table 2: Symptoms of MCD 20
Table 3: Diagnostic Tests and Typical Criteria for MCD 22
Table 4: Treatment Guidelines for MCD 25
Table 5: Most Prescribed Drugs for MCD by Class in the 7MM, 2012 28
Table 6: Leading Drug Treatments for MCD, 2013 35
Table 7: Product Profile - Avastin 38
Table 8: Avastin SWOT Analysis, 2013 40
Table 9: Global Sales Forecasts ($m) for Avastin, 2012-2022 41
Table 10: Number of High-Prescribing Physicians Surveyed 54

List of Figures

Figure 1: Potential Mechanisms of Diabetes-Induced Microvascular Complications 13
Figure 2: General Treatment Algorithms for MCD 26

The report contains a list of tables and figures describing various market and research related to the industry.